Unexpected effect of verapamil on oral bioavailability of the β‐blocker talinolol in humans

[1]  P. Watkins,et al.  The barrier function of CYP3A4 and P-glycoprotein in the small bowel. , 1997, Advanced drug delivery reviews.

[2]  K. Paull,et al.  P-glycoprotein substrates and antagonists cluster into two distinct groups. , 1997, Molecular pharmacology.

[3]  G. Ecker,et al.  Recent developments in overcoming tumour cell multi-drug resistance , 1997 .

[4]  B. Hirst,et al.  Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption , 1997 .

[5]  Leslie Z. Benet,et al.  Intestinal drug metabolism and antitransport processes : A potential paradigm shift in oral drug delivery , 1996 .

[6]  W. Kirch,et al.  Direct demonstration of small intestinal secretion and site‐dependent absorption of the β‐blocker talinolol in humans , 1996, Clinical pharmacology and therapeutics.

[7]  E. Schuetz,et al.  Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. , 1996, Molecular pharmacology.

[8]  S. Dei,et al.  Reversal of multidrug resistance by verapamil analogues. , 1995, Biochemical pharmacology.

[9]  C. Cordon-Cardo,et al.  Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  L. Benet,et al.  Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy , 1995, Molecular carcinogenesis.

[11]  R. Oertel,et al.  Disposition and bioavailability of the β1‐adrenoceptor antagonist talinolol in man , 1995, Biopharmaceutics & drug disposition.

[12]  U. S. Rao,et al.  Mutation of glycine 185 to valine alters the ATPase function of the human P-glycoprotein expressed in Sf9 cells. , 1995 .

[13]  J. Crowley,et al.  A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A southwest oncology group study , 1995, Cancer.

[14]  W. Kirch,et al.  Elucidation of the structure of talinolol metabolites in man. Determination of talinolol and hydroxylated talinolol metabolites in urine and analysis of talinolol in serum. , 1994, Journal of chromatography. B, Biomedical applications.

[15]  B. Sikic,et al.  Clinical trials of modulation of multidrug resistance pharmacokinetic and pharmacodynamic considerations , 1993, Cancer.

[16]  P. Meredith,et al.  R-verapamil: pharmacokinetics and effects on PR interval, blood pressure and heart rate. , 1993, British journal of clinical pharmacology.

[17]  M. Dietel,et al.  Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein. , 1992, Biochemical pharmacology.

[18]  H. Sewell,et al.  The immunocytochemical localisation and distribution of cytochrome P-450 in normal human hepatic and extrahepatic tissues with a monoclonal antibody to human cytochrome P-450. , 1988, British journal of clinical pharmacology.

[19]  C. Peterson,et al.  D‐verapamil and L‐verapamil are equally effective in increasing vincristine accumulation in leukemic cells in vitro , 1988, International journal of cancer.

[20]  M C Willingham,et al.  Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[21]  C H Nightingale,et al.  Basic principles of pharmacokinetics. , 1987, Clinics in laboratory medicine.

[22]  T. Tsuruo,et al.  Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. , 1981, Cancer research.

[23]  H. Fiehring,et al.  On the clinical pharmacology of talinolol, a new beta 1-adrenoceptor blocking agent. , 1979, International journal of clinical pharmacology and biopharmacy.

[24]  M. Eichelbaum,et al.  The metabolism of DL-[14C]verapamil in man. , 1979, Drug metabolism and disposition: the biological fate of chemicals.

[25]  P. Ader,et al.  P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound. , 1998, International journal of clinical pharmacology and therapeutics.

[26]  W T Bellamy,et al.  P-glycoproteins and multidrug resistance. , 1996, Annual review of pharmacology and toxicology.

[27]  I. Pastan,et al.  In vivo models of P-glycoprotein-mediated multidrug resistance. , 1994, Cancer treatment and research.

[28]  I. Pastan,et al.  Biochemistry of multidrug resistance mediated by the multidrug transporter. , 1993, Annual review of biochemistry.